title: Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study.
abstract: OBJECTIVE
  To investigate whether selective serotonin reuptake inhibitor use is associated with an increased risk of cataract surgery.
  
  
  METHODS
  Population-based case-control study.
  
  
  METHODS
  setting: Olmsted County, Minnesota. patient population: Eligible patients were county residents in the Rochester Epidemiology Project. Cases included 6024 county residents aged 50+ years who underwent first-eye cataract surgery between January 1, 2004 and December 31, 2011. Controls included 6024 residents who never had cataract surgery and were matched to cases by age, sex, and date of surgery. Logistic regression models were used to compute odds ratios for differences in selective serotonin reuptake inhibitor use between cases and controls, and to adjust for confounding variables. observation procedure: Rochester Epidemiology Project databases were used to assess cataract surgery and selective serotonin reuptake inhibitor treatment. main outcome measure: Selective serotonin reuptake inhibitor use.
  
  
  RESULTS
  In the cataract surgery cohort of 6024 residents, 1024 (17%) were selective serotonin reuptake inhibitor users compared to 788 (13%) in the matched cohort of 6024 residents never having cataract surgery (P < .001). Selective serotonin reuptake inhibitor use of 1 or more years was associated with an increased risk of cataract surgery (odds ratio [OR] = 1.36; 95% confidence interval [CI], 1.23-1.51; P < .001). The associations were similar in women (OR = 1.37; 95% CI, 1.22-1.55; P < .001) and men (OR = 1.34; 95% CI, 1.12-1.61; P = .002). The risk of cataract surgery was highest with citalopram use (OR = 1.53; 95% CI, 1.33-1.77; P < .001).
  
  
  CONCLUSIONS
  Selective serotonin reuptake inhibitor use of 1 or more years in people aged 50+ years is associated with an increased risk of cataract surgery.
authors.affiliation: Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. Electronic address: erie.jay@mayo.edu.
authors.forename: Jay C
authors.initials: JC
authors.lastname: Erie
authors.affiliation: Division of Biomedical Informatics Support System, Mayo Clinic, Rochester, Minnesota.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Brue
authors.affiliation: Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
authors.forename: Alanna M
authors.initials: AM
authors.lastname: Chamberlain
authors.affiliation: Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
authors.forename: David O
authors.initials: DO
authors.lastname: Hodge
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D002386:Cataract / Q000139:chemically induced / Q000453:epidemiology*; D002387:Cataract Extraction / Q000706:statistics & numerical data*; D016208:Databases, Factual; D003866:Depressive Disorder / Q000188:drug therapy; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D008910:Minnesota / Q000453:epidemiology; D016017:Odds Ratio; D011336:Probability; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors